C4 Therapeutics Readying to Open Phase 1/2a Trial of CFT7455
C4 Therapeutics is preparing to launch a clinical trial testing its lead investigational therapy CFT7455 in multiple myeloma and other blood cancers. The…
Diana Campelo Delgado, — 
Articles by
Xpovio Approved in Israel for Some Myeloma, Lymphoma Patients
The Israeli Ministry of Health has approved Xpovio (selinexor), in combination with the corticosteroid dexamethasone, for the treatment of people with multiple myeloma…
FDA Clears Way for Clinical Trial of HDP-101
Heidelberg Pharma has been cleared in the U.S. to begin a clinical trial testing its investigational therapy HDP-101 for the treatment of…
Phase 3 Trial of ATG-010 (Xpovio) for Advanced Myeloma Opens in China
China’s regulatory agency has approved the start of a Phase 3 clinical trial testing ATG-010 (selinexor), in combination with Velcade (bortezomib) and dexamethasone, in …
Dosing Begins in Phase 1 Trial of CERC-007
Cerecor has dosed the first patient in a Phase 1b clinical trial evaluating  CERC-007 as a potential treatment for relapsed or refractory multiple…
First Patient Dosed With CYAD-211, a Potential CAR T-cell Therapy
The first patient has been dosed in Celyad Oncology’s Phase 1 clinical trial evaluating CYAD-211, an investigational donor-derived CAR T-cell therapy for treating relapsed…
Bispecific Antibody Shows Early, Promising Responses in Trial
PF-06863135, a bispecific antibody being developed by Pfizer as an injectable treatment, shows a manageable safety profile and promising response rates at high dose…
FDA Lifts Hold on Phase 1 Trial for Car-T-Cell Therapy UCARTCS1A
The U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on a Phase 1 trial assessing Cellectis’ investigational CAR T-cell therapy,…
